especially during the first few days of therapy. Chemically, it is 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[ Each capsule for oral administration, contains Loxapine succinate, USP, 6.8 mg, 13.6 mg, 34 mg or 68 mg equivalent to 5 mg, 10 mg, 25 mg, or 50 mg of Loxapine base, respectively. It is present as the succinate salt.Each capsule for oral administration, contains Loxapine succinate, USP, 6.8 mg, 13.6 mg, 34 mg or 68 mg equivalent to 5 mg, 10 mg, 25 mg, or 50 mg of Loxapine base, respectively. It is equally effective as other medications in its class. Chemically, it is 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[Each capsule for oral administration, contains loxapine (loxapine (loxapine (loxapine succinate) succinate) succinate) succinate 6.8, 13.6, 34.0 or 68.1 mg equivalent to 5, 10, 25 or 50 mg of loxapine (loxapine (loxapine (loxapine succinate) succinate) succinate) base respectively. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient's needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.Initial dosage of 10 mg twice daily is recommended, although in severely disturbed patients initial dosage up to a total of 50 mg daily may be desirable. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Seizures have been reported in patients receiving loxapine (loxapine (loxapine (loxapine succinate) succinate) succinate) at antipsychotic dose levels, and may occur in epileptic patients even with maintenance of routine Loxapine (loxapine (loxapine (loxapine succinate) succinate) succinate) has an antiemetic effect in animals. The patient should be carefully monitored, since recurrences of NMS have been reported.Loxapine (loxapine (loxapine (loxapine succinate) succinate) succinate) , like other antipsychotics, may impair mental and/or physical abilities, Usual doses of epinephrine may be ineffective because of inhibition of its vasopressor effect by Loxapine.The possibility of ocular toxicity from Loxapine cannot be excluded at this time. Important Data: Loxapine is a first generation antipsychotic used to treat the symptoms of schizophrenia. The effect that Given these considerations, antipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. These symptoms are usually not severe and can be controlled by reduction of Loxapine dosage or by administration of antiparkinson drugs in usual dosage.Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Hepatocellular injury (i.e., SGOT/SGPT elevation) has been reported in association with Loxapine administration and rarely, jaundice and/or hepatitis questionably related to Loxapine treatment.Weight gain, weight loss, dyspnea, ptosis, hyperpyrexia, flushed facies, headache, paresthesia, and polydipsia have been reported in some patients. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying disease process. However, Loxapine and its metabolites have been shown to be transported into the milk of lactating dogs. 2 Aluminum Lake, FD&C Red No. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. As would be expected from the pharmacologic actions of the drug, the clinical findings may range from mild depression of the CNS and The treatment of overdosage is essentially symptomatic and supportive. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of Loxapine and lorazepam.The risk of using Loxapine in combination with CNS-active drugs has not been systematically evaluated. Early gastric lavage and extended dialysis might be expected to be beneficial. In addition, the 10 mg and 25 mg empty gelatin capsules contain D&C Yellow No. Visit the capsule, green, imprinted with MYLAN 7005, MYLAN 7005capsule, green/yellow, imprinted with MYLAN 7010, MYLAN 7010capsule, green, imprinted with MYLAN 7025, MYLAN 7025capsule, blue/green, imprinted with MYLAN 7050, MYLAN 7050capsule, green/yellow, imprinted with LANNETT, 1395capsule, white/yellow, imprinted with Watson 370, 10 mgcapsule, green/white, imprinted with Watson 371, 25 mgcapsule, blue/white, imprinted with Watson 372, 50 mgcapsule, white/yellow, imprinted with Watson 370, 10 mgcapsule, green/white, imprinted with Watson 371, 25 mgcapsule, blue/white, imprinted with Watson 372, 50 mgCopyright © 2020 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment.